Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review

Awad Al-Omari, D William Cameron, Craig Lee, Vicente F Corrales-Medina, Awad Al-Omari, D William Cameron, Craig Lee, Vicente F Corrales-Medina

Abstract

Background: The role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established.

Methods: We searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the treatment of IE.

Results: Seven observational studies evaluating the use oral beta-lactams (five), oral ciprofloxacin in combination with rifampin (one), and linezolid (one) for the treatment of IE caused by susceptible bacteria reported cure rates between 77% and 100%. Two other observational studies using aureomycin or sulfonamide, however, had failure rates >75%. One clinical trial comparing oral amoxicillin versus intravenous ceftriaxone for streptococcal IE reported 100% cure in both arms but its reporting had serious methodological limitations. One small clinical trial (n = 85) comparing oral ciprofloxacin and rifampin versus conventional intravenous antibiotic therapy for uncomplicated right-sided S. aureus IE in intravenous drug users (IVDUs) reported cure rates of 89% and 90% in each arm, respectively (P =0.9); however, drug toxicities were more common in the latter group (62% versus 3%; P <0.01). Major limitations of this trial were lack of allocation concealment and blinding at the delivery of the study drug(s) and assessment of outcomes.

Conclusion: Reported cure rates for IE treated with oral antibiotic regimens vary widely. The use of oral ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one small clinical trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not possible.

Figures

Figure 1
Figure 1
Flow diagram of the process for the selection of articles included in this review.

References

    1. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;14(18):1318–1330. doi: 10.1056/NEJMra010082.
    1. Que YA, Moreillon P. Infective endocarditis. Nat Rev Cardiol. 2011;14(6):322–336. doi: 10.1038/nrcardio.2011.43.
    1. Wilson WR, Gilbert DN, Bisno AL, Freedman LR, Smith C, Drusano G, Kaye D. Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;14:S89–95.
    1. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006;14(6):1197–1222. doi: 10.1016/j.mcna.2006.07.009.
    1. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;14(23):e394–434. doi: 10.1161/CIRCULATIONAHA.105.165564.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;14(4):264–269. doi: 10.7326/0003-4819-151-4-200908180-00135. W264.
    1. How to read clinical journals: III. To learn the clinical course and prognosis of disease. Can Med Assoc J. 1981;14(7):869–872.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;14(9263):1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. Colli A, Campodonico R, Gherli T. Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis. Ann Thorac Surg. 2007;14(1):87–91. doi: 10.1016/j.athoracsur.2007.02.096.
    1. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989;14(8671):1071–1073.
    1. Chetty S, Mitha AS. High-dose oral amoxycillin in the treatment of infective endocarditis. S Afr Med J. 1988;14(12):709–710.
    1. Pinchas A, Lessing J, Siegman-Igra Y, Liron M. Oral treatment of bacterial endocarditis. Isr J Med Sci. 1983;14(7):646–648.
    1. Phillips B, Watson GH. Oral treatment of subacute bacterial endocarditis in children. Arch Dis Child. 1977;14(3):235–237. doi: 10.1136/adc.52.3.235.
    1. Gray IR, Tai AR, Wallace JG, Calder JH. Oral treatment of bacterial endocarditis with penicillins. Lancet. 1964;14(7351):110–114.
    1. Campeau L, Lefebvre M. Oral treatment of malignant streptococcal endocarditis by potassium phenethicillin: 10 cases. Union Med Can. 1963;14:873–880.
    1. Friedberg CK. Treatment of subacute bacterial endocarditis with aureomycin. J Am Med Assoc. 1952;14(2):98–103.
    1. Schein J, Baehr G. Sulfonamide therapy of subacute bacterial endocarditis. Am J Med. 1948;14(1):66–72. doi: 10.1016/0002-9343(48)90373-8.
    1. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, Vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996;14(1):68–76. doi: 10.1016/S0002-9343(96)00070-8.
    1. Stamboulian D, Bonvehi P, Arevalo C, Bologna R, Cassetti I, Scilingo V, Efron E. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis. 1991;14(Suppl 2):S160–163.
    1. Lafforgue G, Arellano C, Vachoux C, Woodley J, Philibert C, Dupouy V, Bousquet-Melou A, Gandia P, Houin G. Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundam Clin Pharmacol. 2008;14(2):189–201. doi: 10.1111/j.1472-8206.2008.00572.x.
    1. Gordon C, Regamey C, Kirby WM. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother. 1972;14(6):504–507. doi: 10.1128/AAC.1.6.504.
    1. Sutherland R, Croydon EA, Rolinson GN. Amoxycillin: a new semi-synthetic penicillin. Br Med J. 1972;14(5817):13–16. doi: 10.1136/bmj.3.5817.13.
    1. Gray IR. The choice of antibiotic for treating infective endocarditis. Q J Med. 1975;14(175):449–458.
    1. Moreno RA, Boldrina L, Guermani A, Mazucheli J, Sverdloff C, Borges NC. Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2007;14(12):669–676. doi: 10.5414/CPP45669.
    1. Watanakunakorn C. The use of beta-lactam antibiotics in the treatment of septicaemia and endocarditis. Scand J Infect Dis Suppl. 1984;14:110–116.
    1. Sabath LD. Phenoxymethylpenicillin (penicillin V) and phenethicillin. Med Clin North Am. 1970;14(5):1101–1111.
    1. Bolon MK. The newer fluoroquinolones. Infect Dis Clin North Am. 2009;14(4):1027–1051. doi: 10.1016/j.idc.2009.06.003. x.
    1. Kaatz GW, Barriere SL, Schaberg DR, Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987;14(5):753–758. doi: 10.1093/jac/20.5.753.
    1. Zak O, Scheld WM, Sande MA. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis. 1983;14(Suppl 3):S481–490.
    1. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986;14(4):611–613. doi: 10.1128/AAC.29.4.611.
    1. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989;14(8):1184–1187. doi: 10.1128/AAC.33.8.1184.
    1. Tebas P, Martinez Ruiz R, Roman F, Mendaza P, Rodriguez Diaz JC, Daza R, de Letona JM. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis. 1991;14(1):204–205.
    1. Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O'Callaghan RJ. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother. 2004;14(6):1948–1952. doi: 10.1128/AAC.48.6.1948-1952.2004.
    1. Lister PD. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis. 2001;14(Suppl 1):S33–38.
    1. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997;14(8):1662–1667.
    1. Galani L, Pefanis A, Sakka V, Iliopoulos D, Donta I, Triantafyllidi H, Skiadas I, Karayiannakos P, Giamarellou H. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) Int J Antimicrob Agents. 2009;14(1):65–69. doi: 10.1016/j.ijantimicag.2008.07.021.
    1. Berrington AW, Koerner RJ, Perry JD, Bain HH, Gould FK. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol. 2001;14(3):237–239. doi: 10.1078/1438-4221-00126.
    1. Foo SS, Lye DC. Methicillin-sensitive Staphylococcus aureus tricuspid valve endocarditis with annular abscess cured with oral levofloxacin and rifampicin. Int J Antimicrob Agents. 2007;14(3):275–277. doi: 10.1016/j.ijantimicag.2007.04.008.
    1. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. pp. iv7–iv15.
    1. Hall B. The absorption and distribution of aureomycin in man; a review of the literature and study of the concentration of aureomycin in the serum, urine and cerebrospinal fluid after oral administration. Ann Intern Med. 1954;14(4):743–754.
    1. Rolain JM, Boulos A, Mallet MN, Raoult D. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother. 2005;14(7):2673–2676. doi: 10.1128/AAC.49.7.2673-2676.2005.
    1. Rolain JM, Mallet MN, Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis. 2003;14(9):1322–1325. doi: 10.1086/379082.
    1. Cunha BA. Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents. 2010;14(5):517–518. doi: 10.1016/j.ijantimicag.2010.01.017.
    1. Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994;14(7):1515–1518. doi: 10.1128/AAC.38.7.1515.
    1. Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother. 1984;14:17–22.
    1. Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightingale C. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis. 1990;14(4):812–814. doi: 10.1093/infdis/161.4.812.
    1. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;14(5):390–398. doi: 10.7326/0003-4819-117-5-390.
    1. Ono T, Shiota S, Hirota K, Nemoto K, Tsuchiya T, Miyake Y. Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob Agents Chemother. 2000;14(4):1078–1080. doi: 10.1128/AAC.44.4.1078-1080.2000.
    1. McKenna S, Evans G. Macrolides: A Canadian Infectious Disease Society position paper. Can J Infect Dis. 2001;14(4):218–231.
    1. Prunier AL, Malbruny B, Tande D, Picard B, Leclercq R. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother. 2002;14(9):3054–3056. doi: 10.1128/AAC.46.9.3054-3056.2002.
    1. Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, Gill S, Rosenvinge F, Wiggers H, Fuursted K, Holst-Hansen C, Korup E, Schønheyder HC, Hassager C, Høfsten D, Larsen JH, Moser C, Ihlemann N, Bundgaard H. Partial oral treatment of endocarditis. Am Heart J. 2013;14(2):116–122. doi: 10.1016/j.ahj.2012.11.006.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner